Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice  Antonio Alcaraz, Pierre Teillac  European Urology Supplements  Volume 5, Issue 3, Pages 362-368 (April 2006) DOI: 10.1016/j.eursup.2006.01.001 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 The majority of the delegates selected the combination of radiotherapy plus hormone therapy as preferred treatment option for this patient. (a) Localized prostate cancer, specific patient case: 70 yr, T2b, Gleason 7 (4+3) on 6 of 10 cores, PSA level 16ng/ml, moderate symptoms, unfit for surgery, life expectancy about 10 yr. AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; HT=hormone therapy. European Urology Supplements 2006 5, 362-368DOI: (10.1016/j.eursup.2006.01.001) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 LHRH agonists seem to be the preferred treatment option for this patient. (b) Advanced prostate cancer, specific patient case: 74 yr, T3b, N0, M0, Gleason 8 (4+4) on 8/10 cores, PSA level 20ng/ml, moderate symptoms, unfit for surgery, life expectancy about 5–10 yr. AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; HT=hormone therapy. European Urology Supplements 2006 5, 362-368DOI: (10.1016/j.eursup.2006.01.001) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 The majority of the delegates indicated that radiotherapy, closely followed by LHRH agonists, is the preferred treatment option for this patient suffering from biochemical recurrence after initial prostatectomy. (c) Second-line therapy, specific patient case: 68 yr, PSA relapse 4 yr after initial radical prostatectomy (pT2a, PSA 7ng/ml, Gleason 6), PSA DT of 15 mo. AA=antiandrogen; LHRH=luteinizing hormone releasing hormone. European Urology Supplements 2006 5, 362-368DOI: (10.1016/j.eursup.2006.01.001) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 4 Both LHRH agonists and combined androgen blockade seem to be the preferred treatment options for this specific patient. (d) Positive nodes, specific patient case: 74 yr, 7 of 10 cores positive on biopsy, nodes >2cm on computed tomography scan, N+, Mx, Gleason 7 (4+3), PSA 32ng/ml, mild symptoms. AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; CAB=combined androgen blockade. European Urology Supplements 2006 5, 362-368DOI: (10.1016/j.eursup.2006.01.001) Copyright © 2006 Elsevier B.V. Terms and Conditions